Harvard Fellowship Program Will Help FDA Hone AI As Regulatory Tool

May 17, 2018
FDA, as it crafts a new framework to regulate artificial intelligence used in medical products, is simultaneously partnering with Harvard to look into how AI also could be used as a regulatory tool. The goal of the agency's fellowship with Harvard is to create publicly available AI and machine-learning software tools that can be used to analyze FDA data, Laura Maliszewski, the executive director of the Harvard Program in Therapeutic Science at Harvard Medical School, told Inside Health Policy ...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.